Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Current Assets (2021 - 2025)

Bioregenx has reported Current Assets over the past 5 years, most recently at $251265.0 for Q4 2025.

  • For Q4 2025, Current Assets fell 18.37% year-over-year to $251265.0; the TTM value through Dec 2025 reached $251265.0, down 18.37%, while the annual FY2025 figure was $251265.0, 18.37% down from the prior year.
  • Current Assets for Q4 2025 was $251265.0 at Bioregenx, down from $273156.0 in the prior quarter.
  • Over five years, Current Assets peaked at $652664.0 in Q4 2023 and troughed at $676.0 in Q4 2022.
  • A 5-year average of $269757.2 and a median of $283708.5 in 2025 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 97.22% in 2022 and later soared 96447.93% in 2023.
  • Year by year, Current Assets stood at $24358.0 in 2021, then plummeted by 97.22% to $676.0 in 2022, then soared by 96447.93% to $652664.0 in 2023, then crashed by 52.84% to $307796.0 in 2024, then fell by 18.37% to $251265.0 in 2025.
  • Business Quant data shows Current Assets for BRGX at $251265.0 in Q4 2025, $273156.0 in Q3 2025, and $249573.0 in Q2 2025.